baclofen has been researched along with topiramate in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (30.43) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Antonsson, M; Bengtsson, O; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Jerndal, G; Wan, H; Winiwarter, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Choi, HC; Choi, SY; Kang, TC; Kim, DS; Kim, JE; Kim, YI; Kwak, SE; Song, HK; Won, MH | 1 |
| Egli, M; Heilig, M | 1 |
| Johnson, BA | 2 |
| Garbutt, JC | 1 |
| Czyzyk, TA; Sahr, AE; Statnick, MA | 1 |
| Amore, M; Ciccocioppo, R; Donnini, C; Gerra, G; Gerra, ML; Kalluppi, M; Malagoli, M; Raggi, MA; Saracino, MA; Somaini, L | 1 |
| Heinz, A; Müller, CA | 1 |
| Goh, ET; Morgan, MY | 1 |
| Lyon, J | 1 |
| Boussageon, R; Duprez, R; Huneau, A; Laviolle, B; Locher, C; Naudet, F; Palpacuer, C | 1 |
| Donoghue, K | 1 |
| Aletraris, L; Paino, M; Roman, PM | 1 |
| Burnette, EM; Gillis, AJ; Grodin, EN; Hurley, B; Meredith, LR; Miotto, K; Nieto, SJ; Ray, LA | 1 |
| Fomin, V; Goodman, RP; Luther, J; Patel, SJ; Schaefer, E; Shay, JES; Vannier, AGL | 1 |
10 review(s) available for baclofen and topiramate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Disease Models, Animal; Disulfiram; Fructose; Humans; Naltrexone; Neuropeptide Y; Nociceptin; Ondansetron; Opioid Peptides; Receptor, Cannabinoid, CB1; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Taurine; Topiramate | 2006 |
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
Topics: Acamprosate; Alcoholism; Animals; Baclofen; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; Receptors, N-Methyl-D-Aspartate; Ritanserin; Selective Serotonin Reuptake Inhibitors; Taurine; Topiramate | 2008 |
The state of pharmacotherapy for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Delayed-Action Preparations; Disulfiram; Fructose; Humans; Medication Adherence; Naltrexone; Taurine; Temperance; Topiramate | 2009 |
Medication treatment of different types of alcoholism.
Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Chronic Disease; Depressive Disorder; Female; Fructose; Humans; Hypothalamo-Hypophyseal System; Limbic System; Male; Naltrexone; Ondansetron; Pituitary-Adrenal System; Prefrontal Cortex; Receptors, Dopamine D2; Receptors, GABA; Topiramate; Young Adult | 2010 |
Promising medications for cocaine dependence treatment.
Topics: Acetylcysteine; Atomoxetine Hydrochloride; Baclofen; Benzhydryl Compounds; Buprenorphine; Cocaine-Related Disorders; Fructose; Humans; Modafinil; Ondansetron; Patents as Topic; Propylamines; Topiramate | 2011 |
[New treatment options for alcohol dependence].
Topics: Acamprosate; Alcoholism; Baclofen; Combined Modality Therapy; Ethanol; Fructose; Humans; Naltrexone; Psychotherapy; Secondary Prevention; Socioenvironmental Therapy; Substance Withdrawal Syndrome; Taurine; Topiramate | 2013 |
Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Drug Combinations; Fructose; Humans; Naltrexone; Polymorphism, Single Nucleotide; Pyridoxine; Pyrrolidonecarboxylic Acid; Taurine; Topiramate; Treatment Outcome | 2017 |
Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
Topics: Acamprosate; Alcoholism; Baclofen; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topiramate; Treatment Outcome | 2018 |
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Humans; Naltrexone; Topiramate | 2022 |
13 other study(ies) available for baclofen and topiramate
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
Topics: Animals; Blood-Brain Barrier; Brain; Extracellular Fluid; Humans; Linear Models; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
The effect of topiramate on GABA(B) receptor, vesicular GABA transporter and paired-pulse inhibition in the gerbil hippocampus.
Topics: Animals; Baclofen; Blotting, Western; Dentate Gyrus; Excitatory Postsynaptic Potentials; Fructose; GABA Agonists; Gerbillinae; Immunohistochemistry; Neural Inhibition; Neuroprotective Agents; Receptors, GABA-B; Seizures; Topiramate; Vesicular Inhibitory Amino Acid Transport Proteins | 2005 |
Alcohol dependence: after the withdrawal phase. Long-term abstinence: better health and psychosocial status. Psychosocial support for a chronic disorder. Some drugs are useful adjuncts to medical support.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholics; Alcoholism; Anticonvulsants; Baclofen; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; France; Fructose; Health Status; Humans; Naltrexone; Psychotherapy; Randomized Controlled Trials as Topic; Secondary Prevention; Self-Help Groups; Social Support; Taurine; Temperance; Topiramate; Treatment Outcome | 2009 |
A model of binge-like eating behavior in mice that does not require food deprivation or stress.
Topics: Adiposity; Animals; Anti-Obesity Agents; Baclofen; Behavior, Animal; Binge-Eating Disorder; Body Weight; Diet; Disease Models, Animal; Dose-Response Relationship, Drug; Energy Intake; Fluoxetine; Fructose; GABA-B Receptor Agonists; Habituation, Psychophysiologic; Male; Mice; Mice, Inbred C57BL; Selective Serotonin Reuptake Inhibitors; Topiramate | 2010 |
More Treatments on Deck for Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Amines; Baclofen; Cyclohexanecarboxylic Acids; Cytidine Diphosphate Choline; Disulfiram; Drug Repositioning; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Mifepristone; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); Off-Label Use; Patient Acceptance of Health Care; Taurine; Topiramate; United States; Varenicline | 2017 |
Commentary on Palpacuer et al. (2018): Do small effects on total alcohol consumption translate into clinical practice?
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topiramate | 2018 |
The use of off-label medications in substance abuse treatment programs.
Topics: Accreditation; Adrenergic alpha-2 Receptor Agonists; Anticonvulsants; Antiemetics; Baclofen; Clonidine; Excitatory Amino Acid Antagonists; GABA Agents; Gabapentin; Health Facility Size; Humans; Logistic Models; Off-Label Use; Ondansetron; Practice Patterns, Physicians'; Substance Abuse Treatment Centers; Substance-Related Disorders; Time Factors; Topiramate; United States; Valproic Acid | 2020 |
Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder.
Topics: Alcoholism; Baclofen; Female; Gabapentin; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Naltrexone; Retrospective Studies; Topiramate | 2022 |